

Psychedelics in the Treatment of PTSD, Depression, Addiction, and Beyond

Congrès ALBATROS

Paris, France | June 11, 2026



MAPS

MULTIDISCIPLINARY ASSOCIATION
FOR PSYCHEDELIC STUDIES

Rick Doblin, Ph.D.

President & Founder

Rick Doblin, Ph.D.



- President and Founder in 1986 of the Multidisciplinary Association for Psychedelic Studies (MAPS)
- Received doctorate in Public Policy from Harvard's Kennedy School of Government in 2001
- In 2014, the non-profit MAPS founded MAPS Public Benefit Corporation (MAPS PBC), now known as Resilient Pharmaceuticals
- Speaking as President of MAPS, not as a representative of Resilient/Lykos



MAPS

**MULTIDISCIPLINARY ASSOCIATION
FOR PSYCHEDELIC STUDIES**

Psychedelic Healing by Alex Grey (2021)



MAPS
MULTIDISCIPLINARY ASSOCIATION
FOR PSYCHEDELIC STUDIES




Image of *Psychedelic Healing* courtesy of Alex Grey, Chapel of Sacred Mirrors (CoSM).

What Does MDMA-Assisted Therapy Look Like?



An alliance between therapists and participants

- Empathetic rapport and presence
- Support participant's own healing process
- Emphasis on preparation and integration
- Trust in the process



Direction of the session sourced from the participant's experience



An inner-directed therapeutic approach centers on the belief that each person has an intrinsic wisdom and natural ability to heal

maps.org/treatmentmanual.

ADVANCING

Research

CHANGING

Policy

EVOLVING

Education



MAPS

MULTIDISCIPLINARY ASSOCIATION
FOR PSYCHEDELIC STUDIES



MAPS

MULTIDISCIPLINARY ASSOCIATION
FOR PSYCHEDELIC STUDIES

- Funded by donations and grants
- Over \$150 million raised since 1986
- Invaluable volunteer contributions
- Works toward globalization and legalization

Resilient Pharmaceuticals

- Founded by MAPS in 2014 as MAPS Public Benefit Corporation (MAPS PBC)
- Changed name to Lykos Therapeutics in January 2024 after \$100M+ Series A financing
- Changed name to Resilient Pharmaceuticals in August 2025
- MAPS is a minority shareholder

Gracias Family Foundation and CH Foundation Co-Lead \$50M Series B for Resilient/ Lykos

May 30, 2025



Gracias Family Foundation
Antonio Gracias



CH Foundation
Sir Christopher Hohn

Re-emergence of Psychedelic Research

- **Escalating interest in psychedelics as a new therapeutic modality and mechanism**

Presented by Dr. Nora Volkow

Director of U.S. National
Institute on Drug Abuse (NIDA)

American Psychiatric Association
Annual Meeting in San Francisco, CA

May 17, 2026



Bender and Hellerstein. "Assessing the risk–benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research." *Psychopharmacology*, 2022

Q1 2026



Psychedelic Drug Development Tracker



Abbreviations: TRD: Treatment-Resistant Depression; MDD: Major Depressive Disorder; TBI: Traumatic Brain Injury; PTSD: Post-Traumatic Stress Disorder; OUD: Opioid Use Disorder; MUD: Methamphetamine Use Disorder; AUD: Alcohol Use Disorder; SUDs: Substance Use Disorders; SAD: Social Anxiety Disorder; ASD: Autism Spectrum Disorder; IBS: Irritable Bowel Syndrome; OCD: Obsessive Compulsive Disorder; PDD: Premenstrual Dysphoric Disorder; PPD: Postpartum Depression; NCE: New Chemical Entity; GAD: Generalised Anxiety Disorder; ODT: Orally Disintegrating Tablet; RIMA: Reversible Inhibitor of Monoamine Oxidase A; OTF: Oral Thin Film; BDII: Bipolar 2 Disorder; IM: Intramuscular; SL: Sublingual; SC: Subcutaneous; XR: Extended Release; IV: Intravenous; BD: Bipolar Depression; **BTD**: FDA Breakthrough Therapy Designation.

© Psychedelic Alpha, Michael Haichin, 2026.

Other

Supported by

 Patients First.
 Powered by Evidence.



Trump Signs Executive Order to Advance Psychedelic Treatments

April 18, 2026



Podcaster Joe Rogan sent information about ibogaine to the President via text message.

Trump's text response:
"Sounds great. Do you want FDA approval? Let's do it."

The White House. Accelerating Medical Treatments for Serious Mental Illness. Executive Order. April 18, 2026. <https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/>
Image: The White House. April 18, 2026.

FDA Grants Three Commissioner's National Priority Vouchers

April 24, 2026

- Compass Pathways
 - COMP360 (synthetic psilocybin) for treatment-resistant depression
- Usona Institute
 - Psilocybin for major depressive disorder
- Transcend Therapeutics
 - Methylone (MDMA analog) for PTSD



Recent Psychedelic Acquisitions

AbbVie acquires Gilgamesh Pharmaceuticals' bretisilocin for \$1.2 billion

- August 25, 2025
- Novel, short-acting DMT analog
- Phase 2 trials for major depressive disorder (MDD)

Otsuka Pharmaceutical acquires Transcend Therapeutics for \$1.23 billion

- March 27, 2026
- Methylone (MDMA analog) for PTSD, generalized anxiety disorder (GAD), and MDD
- Received FDA National Priority Voucher on April 24, 2026

1. <https://news.abbvie.com/2025-08-25-AbbVie-to-Acquire-Gilgamesh-Pharmaceuticals-Bretisilocin,-a-Novel,-Investigational-Therapy-for-Major-Depressive-Disorder,-Expanding-Psychiatry-Pipeline>

2. <https://www.otsuka-us.com/news/otsuka-pharmaceutical-acquire-transcend-therapeutics-expands-otsuka-portfolio-psychiatric-and>



MDMA

3,4-Methylenedioxymethamphetamine



Increases release of^{1,2}:


- Serotonin (5-HT)
- Norepinephrine (NE)
- Dopamine (DA)

Enhances release of hormones²:

- Oxytocin
- Prolactin
- Vasopressin
- Cortisol

Model of Neurological Effects of PTSD

Difficulty in reducing and eliminating
fear conditioning responses




Rauch SL et al. *Biol Psychiatry*. 2006;60(4):376-382.

Image: Shutterstock.com

Model of Neurological Effects of MDMA

Hypothesized to increase therapeutic alliance
and ability to process traumatic material






SLC6A4* binding site and acute prosocial effects of MDMA are evolutionarily conserved in *Octopus bimaculoides

Eric Edsinger & Gül Dölen
Current Biology (2018)


nature

Letter | [Published: 03 April 2019](#)

Oxytocin-dependent reopening of a social reward learning critical period with MDMA


[Romain Nardou](#), [Eastman M. Lewis](#), [Rebecca Rothhaas](#), [Ran Xu](#), [Aimei Yang](#), [Edward Boyden](#) & [Gül Dölen](#) 

Default Mode Network (DMN)




- Decreased DMN activity with psychedelics
- DMN is critical for self-reflection, self-awareness, and rumination

Time Course of the Acute Subjective Effects in Humans



Time Course of the Critical Period Open State in Mice



MDMA-Assisted Therapy for PTSD

Phase 3 Studies




MAPS

MULTIDISCIPLINARY ASSOCIATION
FOR PSYCHEDELIC STUDIES

Phase 3 Study Design

MDMA-Assisted Therapy for PTSD



1. Mitchell JM, et al. *Nat Med.* 2021;27(6):1025-1033.

2. Mitchell JM, et al. *Nat Med.* 2023;29:2473-2480.

Article | [Open Access](#) | [Published: 10 May 2021](#)


MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study

[Jennifer M. Mitchell](#) , [Michael Bogenschutz](#), [Alia Lilienstein](#), [Charlotte Harrison](#), [Sarah Kleiman](#), [Kelly Parker-Guilbert](#), [Marcela Ot'alora G.](#), [Wael Garas](#), [Casey Paleos](#), [Ingmar Gorman](#), [Christopher Nicholas](#), [Michael Mithoefer](#), [Shannon Carlin](#), [Bruce Poulter](#), [Ann Mithoefer](#), [Sylvestre Quevedo](#), [Gregory Wells](#), [Sukhpreet S. Klaire](#), [Bessel van der Kolk](#), [Keren Tzarfaty](#), [Revital Amiaz](#), [Ray Worthy](#), [Scott Shannon](#), [Joshua D. Woolley](#), ... [Rick Doblin](#)

Phase 3 MAPPI Exploratory Responder Analysis


Two-thirds of participants in MDMA group no longer qualified for a PTSD diagnosis

Therapy + Placebo Group



Therapy + MDMA Group

2-Month Follow-Up



Long-Term Follow-Up
(6-12 Months)

Preliminary findings suggest durable response


- Meet requirements for PTSD diagnosis
- No longer meet requirements for PTSD diagnosis

MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial

Received: 2 June 2023

Accepted: 24 August 2023

Published online: 14 September 2023


 Check for updates

Jennifer M. Mitchell ^{1,2,3}✉, Marcela Ot'alara G. ⁴, Bessel van der Kolk⁵, Scott Shannon⁶, Michael Bogenschutz ⁷, Yevgeniy Gelfand⁸, Casey Paleos⁹, Christopher R. Nicholas¹⁰, Sylvestre Quevedo^{2,11}, Brooke Balliett¹², Scott Hamilton¹³, Michael Mithoefer ¹⁴, Sarah Kleiman¹⁵, Kelly Parker-Guilbert¹⁶, Keren Tzarfaty^{17,18}, Charlotte Harrison¹³, Alberdina de Boer¹⁹, Rick Doblin²⁰, Berra Yazar-Klosinski¹³ & MAPP2 Study Collaborator Group*


Phase 3 MAPP2 Exploratory Responder Analysis

MDMA-Assisted Therapy for PTSD

Therapy with placebo



MDMA-assisted therapy



- Meet requirements for PTSD diagnosis
- No longer meet requirements for PTSD diagnosis

Psychedelic-Assisted Therapy for Substance Use Disorders

Bill W.

Co-Founder of Alcoholics Anonymous



“I am certain that the LSD experience has helped me very much.” (1957)

2012 | Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials




Figure 2. Improvement on alcohol misuse at the first available follow-up after LSD versus control treatments.

^aContinuous outcome data.

MDMA-Assisted Therapy for Alcohol Use Disorder (AUD)



University of Bristol

Sessa B, et al. *J Psychopharmacol*. 2021;35(4):375-383.
Lykos API

VA Launches MDMA-Assisted Therapy Trial for AUD & PTSD

May 26, 2026



- First study of military Veterans with co-occurring diagnosis of alcohol use disorder (AUD) and PTSD
- VA Providence Healthcare System in Rhode Island
- Funded by \$1.5 million, five-year grant from VA
- Data sharing with FDA

US Dept. of Veterans Affairs. News release. May 26, 2026. <https://news.va.gov/press-room/va-launches-mdma-assisted-mental-health-therapy-trial/>

ClinicalTrials.gov ID: NCT07118839

Psilocybin-Assisted Treatment of Alcohol Use Disorder

Presented by Dr. Nora Volkow, Director of NIDA

American Psychiatric Association Annual Meeting | San Francisco, CA | May 17, 2026

POPULATION

53 Men, 42 Women



Adults with alcohol dependence
Mean age, 45.8 y

SETTINGS / LOCATIONS



2 Academic centers in New York and New Mexico

INTERVENTION

95 Individuals randomized



49 Psilocybin
Administered orally in 2 all-day sessions (dose range, 25-40 mg/70 kg)




46 Diphenhydramine control
Administered orally in 2 all-day sessions (dose range, 50-100 mg)

PRIMARY OUTCOME

Percent heavy drinking days (scale, 0-100), assessed using the timeline followback interview, contrasted between groups over the 32-wk period following the first administration of study medication.

FINDINGS

Percent heavy drinking days during the 32-wk double-blind period was lower in the psilocybin group compared with the diphenhydramine group



Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. *JAMA Psychiatry*. Published online August 24, 2022. doi:10.1001/jamapsychiatry.2022.2096


© AMA

Psilocybin for the Treatment of SUD


Presented by Dr. Nora Volkow, Director of NIDA

American Psychiatric Association Annual Meeting | San Francisco, CA | May 17, 2026

Status of Clinical Trials.



% Abstinence Rates at Different Follow-Up Periods




Köck et al. J Subst Abuse Treat.138:108717 (2022)

Psilocybin vs. Nicotine Patch for Smoking Cessation: Pilot Randomized Clinical Trial

Presented by Dr. Nora Volkow, Director of NIDA | American Psychiatric Association Annual Meeting | San Francisco, CA | May 27,

2026



Psilocybin abstinence rates were higher than typical treatments, suggesting promise for tobacco smoking cessation.

Johnson et al. JAMA Netw Open. 2026 Mar 2;9(3):e260972

Johns Hopkins Receives First Federal Grant for Psychedelic Research in 50 Years

October 2021



- Almost \$4 million from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH)
- Psilocybin for tobacco addiction / smoking cessation
- Principal Investigator: Matthew Johnson, Ph.D.


Johns Hopkins Medicine News Release. October 18, 2021. <https://www.hopkinsmedicine.org/news/newsroom/news-releases/2021/10/johns-hopkins-medicine-receives-first-federal-grant-for-psychedelic-treatment-research-in-50-years>

Image: A cluster of Psilocybe cubensis. Credit: Paul Stamets via Hopkins Medicine.

Psilocybin in the Treatment of Cocaine Use Disorder: RCT


Presented by Dr. Nora Volkow, Director of NIDA

American Psychiatric Association Annual Meeting | San Francisco, CA | May 17, 2026




No Serious Adverse Events

- No rescue medications administered.
- All expected adverse events (primarily occurring during the all-day drug session) resolved completely with no sequelae.



Significantly Higher Abstinance



Reduced Risk of Lapse

Ibogaine for Opiate Addiction



MAPS-sponsored observational studies of the long-term efficacy of ibogaine-assisted therapy for opiate addiction

- Mexico
 - Data collection began: 2010
 - Results published: 2018¹
- New Zealand
 - Data collection began: 2012
 - Results published: 2018²

1. Brown TK, Alper K. *Am J Drug Alcohol Abuse*. 2018;44(1):24-36.

2. Noller GE, Frampton CM, Yazar-Klosinski B. *Am J Drug Alcohol Abuse*. 2018;44(1):37-46.

Ibogaine-Assisted Therapy for Dependence on Stimulant and Other Non-Opiate Drugs

“In Brazil there is not a big problem about opiates abuse; the main problem is cocaine and crack/cocaine.”

—Dr. Bruno Rasmussen Chaves

2014 study in the *Journal of Psychopharmacology*

- Analyzed data from 75 previous users of alcohol, cannabis, cocaine, and crack (72% poly-drug users)
- 61% of participants were abstinent after ibogaine treatment




1. Dr. Bruno Rasmussen Chaves. Entheo-Science. <https://entheo-science.de/dr-bruno-rasmussen-chaves-online/>

2. Schenberg EE, de Castro Comis MA, Chaves BR, da Silveira DX. Treating drug dependence with the aid of ibogaine: a retrospective study. *J Psychopharmacol.* 2014;28(11):993-1000.

MDMA-Assisted Couples Therapy



Regulation of Couples Therapy



- FDA has never approved a treatment for a mental health indication that is not listed in the DSM, such as impairment of relationship functioning.
- No legal barriers technically prevent FDA from deviating from precedent by approving a treatment, like couples therapy, for a non-DSM condition.
- However, it will likely require significant legal and political advocacy.

“Research on psychedelics could provide insights into wellness that could augment psychiatry’s historic focus on illness and disorder.”

—Nora D. Volkow, M.D.

Director, National Institute on Drug Abuse (NIDA)

January 13, 2026



Group Therapy

MDMA-Assisted Therapy

Portland VA

MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans (MPG1)

Chris Stauffer, M.D.

Physician Scientist at the Portland VA Medical Center

- 4 cohorts of 6 Veterans with PTSD with 4 therapists
- 2 or 3 MDMA-assisted therapy sessions
 - First session: Individual
 - Second session: Group
 - Third session (for final two cohorts): Group



MDMA-Assisted Group Therapy with Undercover Combat Veterans



Ronen Sidi

Head of the Psychedelic Research Center
HaEmek Hospital, Israel

- 4 therapists for 6 participants
 - 2 primary facilitators and 2 helpers
- 3 MDMA-assisted therapy sessions
 - First and second sessions: Individual
 - Third session: Group

MAPS Israel: Group vs. Individual MDMA-Assisted Therapy for PTSD



Keren Tzarfaty, PhD, MFT

- An Open-Label, Multicenter, Randomized, Non-Inferiority Study to Evaluate the Safety and Effectiveness of **Group vs. Individual** MDMA-Assisted Therapy in PTSD Patients Diagnosed Following the Events of October 7, 2023
- Groups of 7 participants with 4 therapists



SUPPORTING
— WOUNDED —
VETERANS

- Gilly Norton, Supporting Wounded Veterans
- Cambridge University
- 60 participants with PTSD

Toward a World of Net-Zero Trauma by 2070

HEALING FOR ALL
HEALING FOR ALL
HEALING FOR ALL
HEALING FOR ALL
HEALING FOR ALL
HEALING FOR ALL



MAPS

MULTIDISCIPLINARY ASSOCIATION
FOR PSYCHEDELIC STUDIES

Building on Gross National Happiness and Global Peace Index,

MAPS Envisions a Measure of Gross National Trauma

Gross National Happiness

Bhutan

A measure of wellbeing among the Bhutanese population¹

Global Peace Index

Institute for Economics and Peace

A measure of national peacefulness ranking 163 countries²

Gross National Trauma

- MAPS to partner with experts to develop an index that measures the burden of trauma in individuals diagnosed with PTSD *and* those with subthreshold PTSD
- MAPS proposes to track this index to measure impact of prescription and post-prohibition availability of psychedelics until 2070 and beyond

1. GNH Centre Bhutan. <https://www.gnhcentrebhutan.org/>

2. Institute for Economics & Peace. Global Peace Index 2022. <https://www.economicsandpeace.org/wp-content/uploads/2022/06/GPI-2022-web.pdf>

Ukraine

Treating people with PTSD from the war in Ukraine

- First, Ukrainian laws must change to permit research with psychedelics.
- May 6, 2026: Meeting at European Parliament in Brussels to advance psychedelic-assisted therapies in Ukraine



UPRA
Ukrainian Psychedelic
Research Association



Prioritizing **global** communities
with the **largest burden** of trauma
and **fewest resources** for treatment



April 18, 2026